Morgan Stanley lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 6.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,825,855 shares of the medical research company’s stock after selling 194,979 shares during the period. Morgan Stanley owned about 1.47% of IQVIA worth $545,785,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. TRU Independence Asset Management 2 LLC purchased a new stake in IQVIA during the fourth quarter valued at approximately $27,000. Encompass Wealth Advisors LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $27,000. CVA Family Office LLC purchased a new stake in shares of IQVIA in the 1st quarter worth $29,000. Wealthcare Advisory Partners LLC bought a new position in IQVIA in the 1st quarter worth $33,000. Finally, Safeguard Investment Advisory Group LLC purchased a new position in IQVIA during the fourth quarter valued at $34,000. 86.31% of the stock is currently owned by institutional investors.
IQV has been the topic of a number of analyst reports. KeyCorp lifted their price objective on IQVIA from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, May 14th. Truist upped their price target on shares of IQVIA from $235.00 to $260.00 in a research report on Monday, April 26th. Jefferies Financial Group raised their price objective on shares of IQVIA from $259.00 to $273.00 and gave the company a “buy” rating in a research report on Friday, April 23rd. upped their target price on shares of IQVIA from $225.00 to $265.00 in a report on Friday, April 23rd. Finally, Truist Securities raised their price target on IQVIA from $235.00 to $260.00 and gave the company a “buy” rating in a report on Monday, April 26th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $248.84.
IQVIA (NYSE:IQV) last posted its earnings results on Thursday, April 22nd. The medical research company reported $2.18 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.33. IQVIA had a return on equity of 20.96% and a net margin of 3.40%. The firm had revenue of $3.41 billion during the quarter, compared to the consensus estimate of $3.18 billion. During the same period in the prior year, the company earned $1.50 EPS. The company’s quarterly revenue was up 23.8% compared to the same quarter last year. Equities analysts predict that IQVIA Holdings Inc. will post 8.15 EPS for the current fiscal year.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Article: How is net asset value different from market price?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.